COMMUNIQUÉS West-GlobeNewswire

PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth
26/02/2026
Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational discipline Strong revenue outlook, procedure growth, expanding [...]
Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin [...]
Cronos Group Reports 2025 Fourth Quarter and Full-Year Results
26/02/2026
Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million ; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 million Achieved record net revenue in Q4 2025 and FY 2025 Eighth consecutive [...]
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
26/02/2026
JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate [...]
ImageneBio to Participate in Leerink Global Healthcare Conference
26/02/2026
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink [...]
Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
26/02/2026
Revenue and Adjusted EBITDA results delivered in line with stated full-year targets Full‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2, [...]
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
26/02/2026
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the [...]
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
26/02/2026
Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 [...]
Aveanna Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call
26/02/2026
ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its fourth quarter and full year results before the market open on [...]
Enovis Announces Fourth Quarter and Full Year 2025 Results
26/02/2026
Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 [...]
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
26/02/2026
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA [...]
Trading by management and close relations of management
26/02/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
Invitation to the 2026 Annual General Meeting
26/02/2026
The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the [...]
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
26/02/2026
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter [...]
Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
All 2025 Operating and Financial Metrics At or Above High End of Guidance Ranges Full-year 2025 Net Income +59.3% from 2024 Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024 Full-year 2025 Net Cash [...]
Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases
26/02/2026
Wuppertal, Germany, February 26, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that it has entered into a definitive agreement under which Asahi Kasei, through its wholly owned U.S. subsidiary [...]
Pulselight to host senior health leaders for panel on ‘efficiency drive’ to reduce NHS waste and duplication
26/02/2026
Former UK Health Minister Lord Bethell and former Deputy Chief Medical Officer Professor Sir Jonathan Van-Tam, join Pulselight for panel on unlocking NHS efficiency LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pulselight, [...]
Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12
26/02/2026
Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the [...]
Phonak ambassadors spotlight hearing health for the next generation on World Hearing Day
26/02/2026
STÄFA, Switzerland, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Phonak, a global leader in innovative hearing solutions, will mark World Hearing Day on March 3 with a global campaign across three continents, putting youth hearing [...]

Pages